# Fiscal Year 2019 Tuberous Sclerosis Complex Research Program

**Reference Table of Award Mechanisms and Submission Requirements**

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Exploration – Hypothesis Development Award** | Investigators at all academic levels (or equivalent), including postdoctoral fellows | • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field.  
• Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.104(d)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.  
• **Preliminary data not required.**  
• Clinical trials not allowed. | • The maximum period of performance is 2 years.  
• The maximum allowable funding for the entire period of performance is **$150,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. |  
| **Go to:** | | | |  
| • Program Announcement | | | | Pre-Application (Letter of Intent):  
Jul 9, 2019  
5:00 p.m. Eastern time (ET)  
| • General Application Instructions | | | | Application:  
Jul 25, 2019  
11:59 p.m. ET |  
| **Grants.gov Funding Opportunity Number:** | | | |  
| W81XWH-19-TSCRP-EHDA | | | |  
| **Idea Development Award** | Established Investigators:  
Independent investigators at or above the level of Assistant Professor (or equivalent)  
**or**  
New Investigators:  
Independent investigators at or below the level of Assistant Professor (or equivalent) **or**  
Established Investigators in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC | • Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.  
• **Preliminary data expected.**  
• Clinical trials not allowed.  
• **New Investigator Option** supports the continued development of promising independent investigators that are early in their faculty appointments **and/or** the transition of established investigators from other research fields into a career in the field of TSC research.  
• Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. | • The maximum period of performance is 3 years.  
• The maximum allowable funding for the entire period of performance is **$450,000** in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. |  
| **Go to:** | | | |  
| • Program Announcement | | | | Pre-Application (Letter of Intent):  
Jul 9, 2019  
5:00 p.m. Eastern time (ET)  
| • General Application Instructions | | | | Application:  
Jul 25, 2019  
11:59 p.m. ET |  
<p>| <strong>Grants.gov Funding Opportunity Number:</strong> | | | |<br />
| W81XWH-19-TSCRP-IDA | | | |</p>
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Clinical Translational Research Award | Independent Investigators at or above the level of Assistant Professor (or equivalent) | • Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.  
• Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.  
• Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies.  
• Preclinical studies may be appropriate but must include a clinical component.  
• Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.  
• Projects that are exploratory and/or strictly animal research will not be considered for funding.  
• *Preliminary data required.* | • The maximum period of performance is 3 years.  
• The maximum allowable funding for the entire period of performance is $600,000 in direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | 
| Grants.gov Funding Opportunity Number: W81XWH-19-TSCRPCTRA | Go to:  
• Program Announcement  
• General Application Instructions | Pre-Application (Letter of Intent):  
July 9, 2019  
5:00 p.m. ET  
Application:  
July 25, 2019  
11:59 p.m. ET |